Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis

Brain

Volumn 129, Issue 10, 2006, Pages 2635-2647

  Tischner, Denise ^a   Weishaupt, Andreas ^a   Van Den Brandt, Jens ^a   Müller, Nora ^a   Beyersdorf, Niklas ^a   Ip, Chi Wang ^a   Toyka, Klaus V ^a   Hünig, Thomas ^a   Gold, Ralf ^b   Kerkau, Thomas ^a   Reichardt, Holger M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cell migration; CXCR 3; Experimental autoimmune encephalomyelitis; Immunotherapy; Regulatory T cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JJ316; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CD4+ CD25+ T LYMPHOCYTE; CELL INTERACTION; CELL LINE; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; TRANSGENIC ANIMAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; BLOOD-BRAIN BARRIER; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICROSCOPY, CONFOCAL; MODELS, ANIMAL; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW; RECEPTORS, CHEMOKINE; SPINAL CORD; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 33749464498     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl213     Document Type: Article

References (50)

1. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001; 166: 3008-18.
2. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigenspecific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981; 11: 195-9.
3. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445-55.
4. Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol 2005; 17: 638-42.
5. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-24.
6. Denning TL, Kim G, Kronenberg M. Cutting edge: CD4+CD25+ regulatory T cells impaired for intestinal homing can prevent colitis. J Immunol 2005; 174: 7487-91.
7. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26: 485-95.
8. Eylar EH, Kniskern PJ, Jackson JJ. Myelin basic proteins. Methods Enzymol 1974; 32: 323-41.
9. Flügel A, Willem M, Berkowicz T, Wekerle H. Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med 1999; 5: 843-7.
10. Flügel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547-60.
11. Gold R, Giegerich G, Hartung HP, Toyka KV. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable- region V beta 8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci USA 1995; 92: 5850-4.
12. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-71.
13. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002; 16: 183-91.
14. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004; 199: 1479-89.
15. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Boscke R, Budach W, et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 2005; 106: 1875-83.
16. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6: 745-51.
17. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162: 5317-26.
18. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995; 25: 1391-8.
19. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005; 105: 2877-86.
20. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 4712-6.
21. Lin CH, Hünig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626-38.
22. Lundsgaard D, Holm TL, Hornum L, Markholst H. In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes 2005; 54: 1040-7.
23. Mackay IR. Science, medicine and the future: tolerance and autoimmunity. Br Med J 2000; 321: 93-6.
24. Maerten P, Shen C, Bullens DM, Van Assche G, Van Gool S, Geboes K, et al. Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. J Autoimmun 2005; 25: 112-20.
25. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005; 175: 3025-32.
26. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, et al. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 2003; 141: 132-40.
27. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005; 52: 2212-21.
28. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170: 3939-43.
29. Ott PA, Anderson MR, Tary-Lehmann M, Lehmann PV. CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes. Cell Immunol 2005; 235: 1-11.
30. Owens T, Wekerle H, Antel J. Genetic models for CNS inflammation. Nat Med 2001; 7: 161-6.
31. Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S. Impaired postthymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol 2005; 174: 4081-9.
32. Ransohoff RM. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 2006; 27: 167-8.
33. Renno T, Taupin V, Bourbonniere L, Verge G, Tran E, De Simone R, et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12: 376-89.
34. Rodriguez-Palmero M, Hara T, Thumbs A, Hünig T. Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur J Immunol 1999; 29: 3914-24.
35. Rodriguez-Palmero M, Franch A, Castell M, Pelegri C, Perez-Cano FJ, Kleinschnitz C, et al. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 2006; 33: 110-8.
36. Sarween N, Chodos A, Raykundalia C, Khan M, Abbas AK, Walker LS. CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression and tissue invasion. J Immunol 2004; 173: 2942-51.
37. Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003a; 140: 143-52.
38. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003b; 126: 1895-904.
39. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
40. Sorensen TL, Trebst C, Kivisakk P, Klaege KL, Majmudar A, Ravid R, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002; 127: 59-68.
41. Swanborg RH. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 2001; 184: 129-35.
42. Tacke M, Hanke G, Hanke T, Hünig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-47.
43. van den Brandt J, Voss K, Schott M, Hünig T, Wolfe MS, Reichardt HM. Inhibition of Notch signaling biases rat thymocyte development towards the NK cell lineage. Eur J Immunol 2004a; 34: 1405-13.
44. van den Brandt J, Wang D, Kwon SH, Heinkelein M, Reichardt HM. Lentivirally generated eGFP-transgenic rats allow efficient cell tracking in vivo. Genesis 2004b; 39: 94-9.
45. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-9.
46. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-44.
47. Wing K, Suri-Payer E, Rudin A. CD4+CD25+-regulatory T cells from mouse to man. Scand J Immunol 2005; 62: 1-15.
48. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, et al. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 2003; 73: 771-80.
49. Yura M, Takahashi I, Serada M, Koshio T, Nakagami K, Yuki Y, et al. Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2001; 17: 17-25.
50. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995; 54: 540-7.